AUTOIMMUNE DISEASES ASSOCIATED WITH AUTOIMMUNE HEPATITIS

N. Trad, A. Mensi, E. Belhadj Mabrouk, S. Ayadi, Y. Zaimi, L. Mouelhi, Y. Said, R. DabbecheCharles Nicolle Hospital, Gastroenterology, Tunis, Tunisia  Background Autoimmune hepatitis (AIH) is a rare pathology characterized by necrotic-inflammatory hepatocyte lesions, the presence of autoantibodies, and high sensitivity to corticosteroid treatment. it is often associated with other autoimmune diseases. Objectives Our objective was to study the clinical aspects, associated auto-immune diseases, and response to the treatment of AIH. Methods We conducted a retrospective study including consecutive patients with AIH between January 2000 and December 2018. Results We included twenty-two patients; 21 women and one man with an average age of 46 [18-95]. Jaundice was the most frequent presenting sign (80%). Biology found cytolysis greater than ten times in 45.5% of cases. A predominant hypergammaglobulinemia on IgG was noted in 77.2% of cases. At the time of diagnosis, 59% of patients were in the stage of cirrhosis. Antinuclear antibodies, Anti-smooth muscle antibodies, and Anti-LKM1 antibodies were positive in 47.6%, 41%, and 13.3% of cases, respectively. The liver biopsy was performed in 8 patients (36.3%) with a compatible histological appearance in 7 patients. In 54.5% of cases, an associated autoimmune pathology was noted; the most common were autoimmune thyroiditis (33.3%) and autoimmune hemolytic anemia (33.3%). There were also two cases of Sjögren’s syndrome, one case of systemic lupus erythematosus, and one case of rheumatoid arthritis. An overlap syndrome (AIH-PBC) was found in 22.7% of patients. The combined corticosteroid-azathioprine treatment was prescribed in 15 patients (68.1%). In overlap syndromes, ursodeoxycholic acid has been associated. The mean duration of follow-up was 94.5 months. Under treatment, biochemical remission was achieved in 23% of patients. Conclusion In our study, the prevalence of autoimmune diseases associated with AIH was significant, which would underline the importance of systematic screening for clinical and biological immune manifestations in those patients. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests None Declared. Keywords: Comorbidities DOI: 10.1136/annrheumdis-2023-eular.1549Citation: , volume 82, supplement 1, year 2023, page 2013Session: Diagnostics and imaging procedures (Publication only)